Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Invested Capital (2016 - 2025)

Ptc Therapeutics has reported Invested Capital over the past 14 years, most recently at -$199.3 million for Q4 2025.

  • Quarterly results put Invested Capital at -$199.3 million for Q4 2025, up 81.54% from a year ago — trailing twelve months through Dec 2025 was -$199.3 million (up 81.54% YoY), and the annual figure for FY2025 was -$199.3 million, up 81.54%.
  • Invested Capital for Q4 2025 was -$199.3 million at Ptc Therapeutics, down from -$139.2 million in the prior quarter.
  • Over the last five years, Invested Capital for PTCT hit a ceiling of $573.6 million in Q1 2021 and a floor of -$1.1 billion in Q4 2024.
  • Median Invested Capital over the past 5 years was -$202.5 million (2022), compared with a mean of -$322.1 million.
  • Biggest five-year swings in Invested Capital: crashed 552.73% in 2022 and later skyrocketed 86.56% in 2025.
  • Ptc Therapeutics' Invested Capital stood at $60.7 million in 2021, then crashed by 552.73% to -$274.9 million in 2022, then tumbled by 190.38% to -$798.4 million in 2023, then crashed by 35.21% to -$1.1 billion in 2024, then soared by 81.54% to -$199.3 million in 2025.
  • The last three reported values for Invested Capital were -$199.3 million (Q4 2025), -$139.2 million (Q3 2025), and -$187.4 million (Q2 2025) per Business Quant data.